Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study

BMJ : British Medical Journal
B FrankD Kapur

Abstract

To compare the analgesic efficacy and side effects of the synthetic cannabinoid nabilone with those of the weak opioid dihydrocodeine for chronic neuropathic pain. Randomised, double blind, crossover trial of 14 weeks' duration comparing dihydrocodeine and nabilone. Outpatient units of three hospitals in the United Kingdom. 96 patients with chronic neuropathic pain, aged 23-84 years. The primary outcome was difference between nabilone and dihydrocodeine in pain, as measured by the mean visual analogue score computed over the last 2 weeks of each treatment period. Secondary outcomes were changes in mood, quality of life, sleep, and psychometric function. Side effects were measured by a questionnaire. Patients received a maximum daily dose of 240 mg dihydrocodeine or 2 mg nabilone at the end of each escalating treatment period of 6 weeks. Treatment periods were separated by a 2 week washout period. Results Mean baseline visual analogue score was 69.6 mm (range 29.4-95.2) on a 0-100 mm scale. 73 patients were included in the available case analysis and 64 patients in the per protocol analysis. The mean score was 6.0 mm longer for nabilone than for dihydrocodeine (95% confidence interval 1.4 to 10.5) in the available case analysis ...Continue Reading

References

Feb 11, 1975·Journal of Clinical Pharmacology·R NoyesA Canter
Jun 1, 1983·Acta Psychiatrica Scandinavica·A S Zigmond, R P Snaith
Dec 10, 1998·JAMA : the Journal of the American Medical Association·M RowbothamL Magnus-Miller
May 18, 1999·Journal of Epidemiology and Community Health·C JenkinsonC Paice
Oct 18, 2000·The Cochrane Database of Systematic Reviews·J E EdwardsR A Moore
Jun 7, 2005·Pharmacology, Biochemistry, and Behavior·Eliot L Gardner

❮ Previous
Next ❯

Citations

Jan 20, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Anna LeichsenringHermann Lübbert
Oct 1, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Elizabeth J Rahn, Andrea G Hohmann
Nov 19, 2008·Nature Clinical Practice. Neurology·Andrew S C Rice
Jun 3, 2008·British Journal of Anaesthesia·R D Hosking, J P Zajicek
Jan 12, 2012·Clinical and Experimental Pharmacology & Physiology·Jarkko KalliomäkiMärta Segerdahl
Apr 21, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·N AttalT Nurmikko
Jan 10, 2008·BMJ : British Medical Journal·Steven P Cohen
Jan 3, 2012·Harm Reduction Journal·Mark Collen
Sep 21, 2011·PloS One·Emmelie BjörklundChristopher J Fowler
Sep 2, 2010·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Henry J McQuay
Apr 30, 2014·Lung India : Official Organ of Indian Chest Society·Surender Kashyap, Kartikeya Kashyap
Apr 15, 2014·Sleep Medicine Reviews·Peter J GatesJan Copeland
Aug 19, 2009·Der Internist·D Rothstein, M Zenz
Sep 1, 2008·Expert Review of Clinical Pharmacology·Marie BessonJules Desmeules
Sep 1, 2009·Expert Review of Clinical Pharmacology·Lisa Hill, Stephan A Schug
Dec 17, 2009·Expert Opinion on Pharmacotherapy·Dana TurcotteMike Namaka
Oct 8, 2014·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Dana TurcotteMike Namaka
Jan 20, 2016·Pain·Rafael MaldonadoDavid Cabañero
Oct 25, 2011·Critical Reviews in Oncology/hematology·Daniel W BowlesAntonio Jimeno
Mar 1, 2016·Pharmacotherapy·Corey C Tsang, Mirella G Giudice
Mar 24, 2011·British Journal of Clinical Pharmacology·Mary E Lynch, Fiona Campbell
Mar 1, 2012·Statistics in Medicine·Weang Kee HoLauren R Rodgers
Nov 23, 2010·Pain Practice : the Official Journal of World Institute of Pain·Jennifer A Bestard, Cory C Toth
Dec 17, 2014·CA: a Cancer Journal for Clinicians·Joan L Kramer
Jun 18, 2014·Journal of Pain and Symptom Management·Barliz WaissengrinIdo Wolf
Nov 2, 2013·General Hospital Psychiatry·Andrew J Saxon, Kendall W Browne
Apr 22, 2015·The Journal of Physiological Sciences : JPS·Ahmet AltunNedim Durmus
Oct 16, 2012·Pharmacology, Biochemistry, and Behavior·Adrianne R Wilson-PoeMichael M Morgan
Aug 26, 2014·The International Journal of Biochemistry & Cell Biology·Patrick McDonoughEric J Downer
May 16, 2014·Journal of Burn Care & Research : Official Publication of the American Burn Association·Helene Retrouvey, Shahriar Shahrokhi
Jun 12, 2016·The Journal of Pain : Official Journal of the American Pain Society·Barth WilseyAmy Phan
Nov 16, 2016·The International Journal of Neuroscience·Yuchao Shang, Yuying Tang
Apr 24, 2012·Statistical Methods in Medical Research·John N S MatthewsLauren R Rodgers
Apr 19, 2018·Journal of the American Geriatrics Society·Joshua Briscoe, David Casarett
Mar 8, 2018·The Cochrane Database of Systematic Reviews·Martin MückeWinfried Häuser
Oct 7, 2017·Current Rheumatology Reports·E Alfonso Romero-SandovalP Abigail Alvarado-Vázquez
Mar 30, 2011·The American Journal of Hospice & Palliative Care·Gregory T CarterLester Grinspoon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.